Boston Scientific Corporation

NYSE:BSX

Medical - Devices

Healthcare
$43.64 +1.00%

+$0.45 today

Market cap
$63.25B
Beta
0.56
P/E (TTM)
19.0
EPS (TTM)
$2.39
52W Low $44.44High $109.50

Volume 13.21M

Average 19.45M

BSX Net Income

Bottom-line profit after all expenses, interest, and taxes.

Boston Scientific CorporationNYSE: BSX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $907M rose 14.4% year over year, behind the +46.6% change in trailing-twelve-month net income. Sequentially, it fell 32.2% from the prior quarter. Over 3 fiscal years it compounded at +60.5% a year.

Context

  • Net income amounted to 14.4% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 21 analysts of $4.73B (+63.8%) for the fiscal year ending Dec 2026, a step up from the +55.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$907M-32.2% QoQ
Last fiscal yearDec 2025
$2.89B+55.7% YoY
LTMJun 2026
$3.67B+46.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%+39.8%+25.4 pp
1 year+55.7%+63.8%+8.1 pp
3-year CAGR+60.5%+19.0%-41.5 pp
5-year CAGR+15.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
2.89B USD
Year-over-year change
+55.7%
4-year CAGR
+29.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BSX compares with its peers on the latest reported figures

  • BSX's LTM Jun 2026 net income of $3.67B is the 2nd highest of the 11 companies compared; the peer median is $107.48M.
  • Its year-over-year change of +46.6% is the 3rd highest of 11, against a peer median of +10.5%.
  • Net income amounts to 17.5% of revenue for BSX, versus a peer median of 11.8%.
BSX Competitors Peer median
Net Income for BSX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$5.23B +12.2%+8.5%13.9%
BSXBoston Scientific CorporationLTM Jun 2026$3.67B +46.6%+60.5%17.5%
EWEdwards Lifesciences CorporationLTM Jun 2026$1B -75.8%-11.0%15.4%
LIVNLivaNova PLCLTM Sep 2026$196.08M +190.2%—13.0%
PENPenumbra, Inc.LTM Jun 2026$160.59M +8.7%—10.7%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M +35.2%+19.9%9.9%
CNMDCONMED CorporationLTM Mar 2026$54.85M -53.8%—4.0%
ATRCAtriCure, Inc.LTM Jun 2026$10.55M +129.0%—1.9%
ANGOAngioDynamics, Inc.LTM Feb 2026-$31.39M +24.2%—10.0%
CVRXCVRx, Inc.LTM Mar 2026-$52.66M -2.2%—89.1%
TFXTeleflex IncorporatedLTM Jun 2026-$1.03B -636.3%—39.6%
Peer median (excluding BSX) $107.48M+10.5%+8.5%11.8%

Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.89B12.68B14.24B16.75B20.07B
Cost of Revenue4.43B4.97B5.41B6.48B6.22B
Gross Profit7.46B7.71B8.83B10.27B13.85B
Gross Margin62.8%60.8%62.0%61.3%69.0%
Research & Development1.2B1.32B1.41B1.62B2.05B
Selling, General & Admin4.29B4.52B5.19B5.98B6.89B
Operating Expenses5.54B5.89B6.65B7.63B9.88B
Depreciation & Amortization1.09B1.14B1.2B1.27B1.37B
EBITDA2.52B2.74B3.45B3.94B5.1B
EBITDA Margin21.2%21.6%24.2%23.5%25.4%
Operating Income1.92B1.82B2.18B2.64B3.97B
Operating Margin16.2%14.4%15.3%15.7%19.8%
Interest Income4M10M22M107M0
Interest Expense349M464M272M387M349M
Other Income / Expenses(846M)(683M)(196M)(353M)(586M)
Income Before Tax1.08B1.14B1.99B2.28B3.39B
Pre-Tax Margin9.1%9.0%13.9%13.6%16.9%
Income Tax Expense36M443M393M436M493M
Net Income1.04B698M1.59B1.85B2.89B
Net Margin8.7%5.5%11.2%11.1%14.4%
EPS (Basic)0.690.451.081.261.96
EPS (Diluted)0.690.451.071.251.94
Weighted Avg Shares1.42B1.43B1.45B1.47B1.48B
Weighted Avg Shares (Diluted)1.43B1.44B1.46B1.49B1.49B

Boston Scientific Corporation

NYSE:BSX

Intrinsic Alpha fair value

Locked

Current Price

$43.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.